B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients.
Stefan T G BruijnenMichel Tsang-A-SjoeHennie RatermanTamara RamwadhdoebeDaniëlle VugtsGuus van DongenMarc HuismanOtto HoekstraPaul-Peter TakAlexandre VoskuylConny van der LakenPublished in: Arthritis research & therapy (2016)
Non-invasive B-cell imaging by 89Zr-rituximab PET-CT has promising clinical value to select RA responders to rituximab at baseline. 89Zr-rituximab PET-CT may also hold promise for monitoring anti-B-cell therapies in other B-cell driven autoimmune diseases, such as systemic lupus erythematosus and Sjögren's disease.
Keyphrases
- pet ct
- diffuse large b cell lymphoma
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis patients
- chronic lymphocytic leukemia
- hodgkin lymphoma
- positron emission tomography
- high resolution
- rheumatoid arthritis
- pet imaging
- ankylosing spondylitis
- big data
- machine learning
- computed tomography
- systemic sclerosis
- combination therapy
- idiopathic pulmonary fibrosis